血清外泌体中CDK6和RHOU mRNA可作为无功能垂体腺瘤侵袭性的标志物

于姗; 王小爽; 曹开灿; 包新杰; 余佳

doi:10.24920/003585

Your Location：

Home >

Browse articles >

血清外泌体中CDK6和RHOU mRNA可作为无功能垂体腺瘤侵袭性的标志物

中国医学科学杂志（英文版） 2019年34卷第3期页码：168-176

Original Article | Updated：2024-04-10

- 血清外泌体中CDK6和RHOU mRNA可作为无功能垂体腺瘤侵袭性的标志物
- Affiliations：
  
  1. 1 State Key Laboratory of Medical Molecular Biology & Key Laboratory of RNA and Hematopoietic Regulation & Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
  2. 2 Department of Thoracic Surgery, Nanfang Hospital, Guangzhou 510515, China
  3. 3 Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Author bio：
  
  *Xinjie Bao, Tel: 86-18001182406, E-mail: xinjieabao@163.com;
  Jia Yu, Tel: 86-10-69156423, E-mail: j-yu@ibms.pumc.edu.cn
- Funds：
  
  Supported by the National Natural Science Foundation of China(31725013);CAMS Innovation Fund for Medical Sciences(2017-I2M-3-009);the Beijing Nova Program(Z181100006218003)
- DOI：10.24920/003585
  中图分类号：
- 收稿日期：2019-05-22，
  
  网络出版日期：2019-05-22，
  
  纸质出版日期：2019-05-22
- Accepted：
Scan QR Code
于姗, 王小爽, 曹开灿, 等. 血清外泌体中CDK6和RHOU mRNA可作为无功能垂体腺瘤侵袭性的标志物[J]. 中国医学科学杂志（英文版）, 2019,34(3):168-176.

Yu Shan, Wang Xiaoshuang, Cao Kaican, et al. Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma[J]. Chinese medical sciences journal, 2019, 34(3): 168-176.
于姗, 王小爽, 曹开灿, 等. 血清外泌体中CDK6和RHOU mRNA可作为无功能垂体腺瘤侵袭性的标志物[J]. 中国医学科学杂志（英文版）, 2019,34(3):168-176. DOI： 10.24920/003585.

Yu Shan, Wang Xiaoshuang, Cao Kaican, et al. Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma[J]. Chinese medical sciences journal, 2019, 34(3): 168-176. DOI： 10.24920/003585.

摘要

目的

探索无功能垂体腺瘤（non-functioning pituitary adenomas

NF-PAs）侵袭性的循环分子标志物。

方法

提取侵袭性NF-PAs（invasive NF-PAs

INF-PAs）和非侵袭性NF-PAs（noninvasive NF-PAs

NNF-PAs）患者外周血血清外泌体RNA

采用数字PCR检测候选基因的表达

检验分析其表达差异。同时利用基因表达值建立受试者工作特征曲线（receiver operating characteristic

ROC）

找出阈值

并计算该阈值区分INF-PAs的正确率、灵敏度、特异度和精度

以评估目的基因对侵袭性的诊断效果。

结果

CDK6和RHOU mRNA在INF-PAs中显著上调。ROC曲线显示:CDK6的曲线下面积为0.772（95%

:0.600-0.943

=0.005）

区分INF-PAs的准确率为77.27%

灵敏度为83.33%

特异度为75.00%

精度为55.56%。RHOU的AUC为0.757（95%

:0.599-0.915

=0.007）

区分准确率为72.73%

灵敏度为83.33%

特异度为68.75%

精度为50.00%。CDK6和RHOU mRNA在NF-PAs患者血清外泌体中的含量呈正相关（

=0.935

0.001）。同时用两个基因的阈值作为预测指标

得到的区分准确率为81.82%

灵敏度为83.33%

特异度为81.25%

精度为62.50%。

结论

血清外泌体中的CDK6和RHOU mRNA分子可作为诊断NF-PA侵袭性的标志物

使用两基因的双阈值诊断可提高准确率、特异度和精度。该结果提示了NF-PAs侵袭性的分子机制

并对侵袭性NF-PAs的早期临床诊断和预后具有重要意义。

Abstract

Objective

To explore circulating biomarkers for screening the invasiveness of non-functioning pituitary adenomas (NF-PAs).

Methods

The exosomal RNAs were extracted from serum of patients with invasive NF-PA (INF-PA) or noninvasive NF-PA (NNF-PA). Droplet digital PCR was adapted to detect the mRNA expression of candidate genes related to tumor progression or invasion

such as cyclin dependent kinase 6 (CDK6)

ras homolog family member U (RHOU)

and spire type actin nucleation factor 2 (SPIRE2). Student’s

-test was used to analyze the statistical difference in the mRNA expression of candidate genes between the two groups. Receiver operating characteristic (ROC) curve was used to establish a model for predicting the invasiveness of NF-PAs. The accuracy

sensitivity

specificity and precision of the model were then obtained to evaluate the diagnostic performance.

Results

CDK6 (0.2600±0.0912

. 0.1789±0.0628

=3.431

=0.0013) and RHOU mRNA expressions (0.2696±0.1118

. 0.1788±0.0857

=2.946

=0.0052) were upregulated in INF-PAs patients’ serum exosomes as compared to NNF-PAs. For CDK6

the area under the ROC curve (AUC) was 0.772 (95%

: 0.600-0.943

=0.005)

the accuracy

sensitivity

specificity and precision were 77.27%

83.33%

75.00% and 55.56% to predict the invasiveness of NF-PAs. For RHOU

the AUC was 0.757 (95%

: 0.599-0.915

=0.007)

the accuracy

sensitivity

specificity and precision were 72.73%

83.33%

68.75% and 50.00%. In addition

the mRNA levels of CDK6 and RHOU in serum exosomes were significantly positively correlated (

=0.935

0.001). After combination of the cut-off scores of the two genes

the accuracy

sensitivity

specificity and precision were 81.82%

83.33%

81.25% and 62.50%.

Conclusions

CDK6 and RHOU mRNA in serum exosomes can be used as markers for predicting invasiveness of NF-PAs. Combination of the two genes performs better in distinguishing INF-PAs from NNF-PAs. These results indicate CDK6 and RHOU play important roles in the invasiveness of NF-PAs

and the established diagnostic method is valuable for directing the clinical screening and postoperative treatment.

关键词

Keywords

references

Asa SL , Ezzat S . The cytogenesis and pathogenesis of pituitary adenomas . Endocr Rev 1998 ; 19 ( 6 ): 798 - 827 . doi: 10.1210/edrv.19.6.0350 10.1210/edrv.19.6.0350 .

Daly AF , Rixhon M , Adam C , et al . High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium . J Clin Endocrinol Metab 2006 ; 91 ( 12 ): 4769 - 75 . doi: 10.1210/jc.2006-1668 10.1210/jc.2006-1668 .

Fernandez A , Karavitaki N , Wass JA . Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) . Clin Endocrinol (Oxf) 2010 ; 72 ( 3 ): 377 - 82 . doi: 10.1111/j.1365-2265.2009.03667.x 10.1111/j.1365-2265.2009.03667.x .

Lopes MBS . The 2017 World Health Organization classification of tumors of the pituitary gland: a summary . Acta Neuropathol 2017 ; 134 ( 4 ): 521 - 35 . doi: 10.1007/s00401-017-1769-8 10.1007/s00401-017-1769-8 .

Selman WR , Laws ER, Jr. , Scheithauer BW , et al . The occurrence of dural invasion in pituitary adenomas . J Neurosurg 1986 ; 64 ( 3 ): 402 - 7 . doi: 10.3171/jns.1986.64.3.0402 10.3171/jns.1986.64.3.0402 .

Thapar K , Kovacs K , Scheithauer BW , et al . Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody . Neurosurgery 1996 ; 38 ( 1 ): 99 - 106 ; discussion 106-7. doi: 10.1097/00006123-199601000-00024 10.1097/00006123-199601000-00024 .

Raverot G , Burman P , McCormack A , et al . European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas . Eur J Endocrinol 2018 ; 178 ( 1 ): G1 - g24 . doi: 10.1530/eje-17-0796 10.1530/eje-17-0796 .

Boriachek K , Islam MN , Moller A , et al . Biological functions and current advances in isolation and detection strategies for exosome nanovesicles . Small 2018 ; 14 ( 6 ). doi: 10.1002/smll.201702153 10.1002/smll.201702153 .

Vlassov AV , Magdaleno S , Setterquist R , et al . Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials . Biochim Biophys Acta 2012 ; 1820 ( 7 ): 940 - 8 . doi: 10.1016/j.bbagen.2012.03.017 10.1016/j.bbagen.2012.03.017 .

Del Re M , Biasco E , Crucitta S , et al . The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients . Eur Urol 2017 ; 71 ( 4 ): 680 - 7 . doi: 10.1016/j.eururo.2016.08.012 10.1016/j.eururo.2016.08.012 .

Knosp E , Steiner E , Kitz K , et al . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings . Neurosurgery 1993 ; 33 ( 4 ): 610 - 7 ; discussion 7 - 8 . doi: 10.1097/00006123-199310000-00008 10.1097/00006123-199310000-00008

Corbisier P , Pinheiro L , Mazoua S , et al . DNA copy number concentration measured by digital and droplet digital quantitative PCR using certified reference materials . Anal Bioanal Chem 2015 ; 407 ( 7 ): 1831 - 40 . doi: 10.1007/s00216-015-8458-z 10.1007/s00216-015-8458-z .

Asa SL , Ezzat S . The pathogenesis of pituitary tumors . Annu Rev Pathol 2009 ; 4 ( 1 ): 97 - 126 . doi: 10.1146/annurev.pathol.4.110807.092259 10.1146/annurev.pathol.4.110807.092259 .

Sav A , Rotondo F , Syro LV , et al . Biomarkers of pituitary neoplasms . Anticancer Res 2012 ; 32 ( 11 ): 4639 - 54 .

Amar AP , Hinton DR , Krieger MD , et al . Invasive pituitary adenomas: significance of proliferation parameters . Pituitary 1999 ; 2 ( 2 ): 117 - 22 .

Knosp E , Kitz K , Perneczky A . Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67 . Neurosurgery 1989 ; 25 ( 6 ): 927 - 30 . doi: 10.1227/00006123-198912000-00012 10.1227/00006123-198912000-00012

Zhao X , Li J , Huang S , et al . MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer . Am J Transl Res 2015 ; 7 ( 8 ): 1382 - 9 .

Mendrzyk F , Radlwimmer B , Joos S , et al . Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma . J Clin Oncol 2005 ; 23 ( 34 ): 8853 - 62 . doi: 10.1200/jco.2005.02.8589 10.1200/jco.2005.02.8589 .

Costello JF , Plass C , Arap W , et al . Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA . Cancer Res 1997 ; 57 ( 7 ): 1250 - 4 .

Bax DA , Mackay A , Little SE , et al . A distinct spectrum of copy number aberrations in pediatric high-grade gliomas . Clin Cancer Res 2010 ; 16 ( 13 ): 3368 - 77 . doi: 10.1158/1078-0432.Ccr-10-0438 10.1158/1078-0432.Ccr-10-0438 .

Nagel S , Leich E , Quentmeier H , et al . Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma . Leukemia 2008 ; 22 ( 2 ): 387 - 92 . doi: 10.1038/sj.leu.2405028 10.1038/sj.leu.2405028 .

Nebenfuehr S , Bellutti F , Sexl V . Cdk6: at the interface of Rb and p53 . Mol Cell Oncol 2018 ; 5 ( 5 ): e1511206 . doi: 10.1080/23723556.2018.1511206 10.1080/23723556.2018.1511206 .

Lee KH , Lotterman C , Karikari C , et al . Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer . Pancreatology 2009 ; 9 ( 3 ): 293 - 301 . doi: 10.1159/000186051 10.1159/000186051 .

Lim JT , Mansukhani M , Weinstein IB . Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells . Proc Natl Acad Sci U S A 2005 ; 102 ( 14 ): 5156 - 61 . doi: 10.1073/pnas.0501203102 10.1073/pnas.0501203102 .

Wang G , Zheng L , Yu Z , et al . Increased cyclin-dependent kinase 6 expression in bladder cancer . Oncol Lett 2012 ; 4 ( 1 ): 43 - 6 . doi: 10.3892/ol.2012.695 10.3892/ol.2012.695 . DOI: 10.3892/ol.2012.695 http://doi.org/10.3892/ol.2012.695

Symons M , Segall JE . Rac and Rho driving tumor invasion: who’s at the wheel? Genome Biol 2009 ; 10 ( 3 ): 213 . doi: 10.1186/gb-2009-10-3-213 10.1186/gb-2009-10-3-213 .

Liu S , Wang Y , Xue W , et al . Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival . Int J Cancer 2017 ; 141 ( 4 ): 721 - 30 . doi: 10.1002/ijc.30785 10.1002/ijc.30785 .

Vega FM , Ridley AJ . Rho GTPases in cancer cell biology . FEBS Lett 2008 ; 582 ( 14 ): 2093 - 101 . doi: 10.1016/j.febslet.2008.04.039 10.1016/j.febslet.2008.04.039 .

Parri M , Chiarugi P . Rac and Rho GTPases in cancer cell motility control . Cell Commun Signal 2010 ; 8 ( 1 ): 23 . doi: 10.1186/1478-811x-8-23 10.1186/1478-811x-8-23 .

Simpson KJ , Dugan AS , Mercurio AM . Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma . Cancer Res 2004 ; 64 ( 23 ): 8694 - 701 . doi: 10.1158/0008-5472.Can-04-2247 10.1158/0008-5472.Can-04-2247 .

Canovas Nunes S , Manzoni M , Pizzi M , et al . The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma . Blood Cancer J 2018 ; 8 ( 2 ): 20 . doi: 10.1038/s41408-018-0053-z 10.1038/s41408-018-0053-z .

Bhavsar PJ , Infante E , Khwaja A , et al . Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration . Oncogene 2013 ; 32 ( 2 ): 198 - 208 . doi: 10.1038/onc.2012.42 10.1038/onc.2012.42 . DOI: 10.1038/onc.2012.42 http://doi.org/10.1038/onc.2012.42

Dart AE , Box GM , Court W , et al . PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion . J Cell Biol 2015 ; 211 ( 4 ): 863 - 79 . doi: 10.1083/jcb.201501072 10.1083/jcb.201501072 .

Hodge RG , Ridley AJ . Regulation and functions of RhoU and RhoV . Small GTPases 2017 ; 30 : 1 - 8 . doi: 10.1080/21541248.2017.1362495 10.1080/21541248.2017.1362495 .

Faure S , Fort P . Atypical RhoV and RhoU GTPases control development of the neural crest . Small GTPases 2015 ; 6 ( 4 ): 174 - 7 . doi: 10.1080/21541248.2015.1025943 10.1080/21541248.2015.1025943 .

浏览量

973

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

暂无数据